R. Bruce Diebold

Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor

Justin A. Caravella, Jian Lin, R. Bruce Diebold et al. · Journal of Medicinal Chemistry · 2020 · 144 citations · Full text

Pharmacy, Oncology, Pharmacology +15

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors

Keith W. Woods, John P. Fischer, Akiyo Claiborne et al. · Bioorganic & Medicinal Chemistry · 2006 · 81 citations

Pharmacy, Medicinal Chemistry, Pharmacology +9

AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

Srividya B. Balachander, Steven W. Criscione, Kate F. Byth et al. · Clinical Cancer Research · 2020 · 69 citations

Medicine, Oncology, Pharmacology +13

Syntheses of Potent, Selective, and Orally Bioavailable Indazole-Pyridine Series of Protein Kinase B/Akt Inhibitors with Reduced Hypotension

Gui‐Dong Zhu, Viraj B. Gandhi, Jianchun Gong et al. · Journal of Medicinal Chemistry · 2007 · 62 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors

Jian Lin, Wei Lu, Justin A. Caravella et al. · Journal of Medicinal Chemistry · 2019 · 47 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15